Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY: JNJ )

166.15 -0.92 (-0.55%)
Official Closing Price Updated: 6:30 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
Johnson & Johnson To Pay $700M To Settle Multi-State Talc Investigation
Although the settlement has been reached, Johnson & Johnson still faces a substantial number of talc-related lawsuits. 
Via Benzinga
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge
The integration of AI and healthcare is well underway. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
2 Stocks You Can Safely Hold for the Long Haul
Some services will always be in high demand. 
Via The Motley Fool
7 Recession-Proof Stocks to Buy Now for Peace of Mind
Dive into the fundamentals behind the resilience of recession-proof stocks and the performance indicators driving their success. 
Via InvestorPlace
The 3 Most Undervalued Robinhood Stocks to Buy in June 2024
These three undervalued Robinhood stocks show the platform's users are much more conventional than critics believe. 
Via InvestorPlace
Uncovering Dividend Opportunities with NYSE:JNJ.
Exploring JOHNSON & JOHNSON (NYSE:JNJ)'s dividend characteristics. 
Via Chartmill
Performance Comparison: Johnson &amp; Johnson And Competitors In Pharmaceuticals Industry
Via Benzinga
Time to Pounce: 2 High-Yielding Dow Stocks That Are Begging to Be Bought Right Now
Among the Dow's 30 components are two high-octane income stocks that have increased their respective payouts for 37 and 62 consecutive years. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
The Safety Net Seven: 7 Stocks to Own for Unshakeable Returns
Although they’re not necessarily the most exciting ideas, investors should turn to safe stocks to buy to manage the market’s ambiguity. 
Via InvestorPlace
3 Stocks to Buy With 20% Upside
All three of these high-quality companies have great upside. 
Via The Motley Fool
The 3 Best Dow Stocks to Buy in June 2024
Discover the three best Dow stocks to buy in June 2024. Invest in these top-performing companies with strong fundamentals. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
AbbVie's Arthritis Drug Humira Retains Market Dominance Despite Biosimilar Competition, Challenges Biosimilar Industry Viability
Humira maintains over 80% of its market share despite facing nine biosimilar rivals, raising concerns about the future of the biosimilar market and prompting calls for regulatory reform to enhance... 
Via Benzinga
The Dividend Darlings: 3 Stocks That Will Shower Your Portfolio with Cash
Dividend stocks have a record of stability and growth. Read here about three picks that are thriving and hiking dividends amid uncertainty. 
Via InvestorPlace
3 Dow Stocks That Are No-Brainer Buys in June
The 30-component Dow Jones Industrial Average has three phenomenal deals hiding in plain sight. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Sleep Easy: 3 Safe Stocks That Won’t Have You Stressin’
Explore three safe stocks to buy with sharp fundamentals in pharmaceuticals, household products, and restaurants. 
Via InvestorPlace
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
From Johnson & Johnson
Via Business Wire
The 3 Most Undervalued Dow Stocks to Buy in June 2024
Some undervalued Dow stocks are starting to look timely as we enter the last month of the first half of 2024. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
3 Dividend Aristocrats to Scoop Up During Market Pullbacks in June
Since three dividend aristocrat stocks have rewarded shareholders for decades, buy them now for a worry-free retirement. 
Via InvestorPlace
Johnson & Johnson Ordered To Pay $260M In Latest Talc Trial
The ruling comes as J&J continues to pursue a proposed $6.48 billion settlement of most talc-related lawsuits through a prepackaged bankruptcy. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Johnson & Johnson At ASCO Highlights Long Term Data From Multiple Myeloma Drug, Shows Sustained Deep, Durable Responses In Pretreated Patients
JNJ announced positive longer-term data from Phase 1/2 study of Tecvayli for RRMM. Results show deep and durable responses with a consistent safety profile. 
Via Benzinga
7 Overlooked Stocks That Belong in Every Portfolio
Looking beyond the headlines creates an opportunity for investors who have the patience to seek must-own overlooked stocks. 
Via InvestorPlace
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points
Eli Lilly is in a buy zone, while rival Novo Nordisk forged a lower entry. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
3 Magnificent Dividend Stocks to Buy and Hold Forever
These dividend stocks are keepers for income investors. 
Via The Motley Fool
Boring Is Beautiful: 3 Blue-Chip Stocks to Buy and Hold Forever
Discover why boring blue-chip stocks like Johnson & Johnson, Sysco, and S&P Global can prove to be excellent long-term investments. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
Johnson & Johnson Completes Acquisition of Shockwave Medical
From Johnson & Johnson
Via Business Wire
3 Sorry Biotech Stocks to Sell in May While You Still Can
Morgan Stanley's bullish outlook highlights the need for strategic trimming of underperforming biotech stocks to sell. 
Via InvestorPlace
Why Sarepta Therapeutics Stock Is Rising Today
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock is trading higher on Thursday after it was announced the company will be added to the S&P MidCap 400. 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Stocks That Could Be Easy Wealth Builders
These investment ideas should help you grow your portfolio with minimal effort. 
Via The Motley Fool
Blue-Chip Bubble Trouble: 7 Stocks to Short as Valuations Stretch to the Limit
Be careful with these overvalued blue-chip stocks, each of which is trading at a high multiple relative to its peers. 
Via InvestorPlace
Johnson & Johnson's Drug Seltorexant Aces Late-Stage Depression Trial
Johnson & Johnson reported successful Phase 3 trial results for seltorexant, an investigational treatment for major depressive disorder with insomnia. 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.